AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Refractory Systemic Lupus Erythematosus

A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus NCT07444307Phase 13 sites๐Ÿ“ Hefei๐Ÿ“ Wuhan๐Ÿ“ Beijing Hangzhou Qihan Biotech Co., Ltd. ยท Tests: QT-019B Cell Injection An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease NCT06379646NA1 site๐Ÿ“ Shanghai China Immunotech (Beijing) Biotechnology Co., Ltd. ยท Tests: YTS109 Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE NCT07233642Phase 11 site๐Ÿ“ Hangzhou The Children's Hospital of Zhejiang University School of Meโ€ฆ ยท Tests: CD19 CAR-T cells CAR-T Cells Therapy for Patients With Autoimmune Diseases NCT07052565NA1 site๐Ÿ“ Hefei Anhui Provincial Hospital ยท Tests: Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases NCT07470151NA1 site๐Ÿ“ Wuhan Union Hospital, Tongji Medical College, Huazhong Universityโ€ฆ ยท Tests: EVM18001 Injection Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases NCT07558850NA1 site๐Ÿ“ Nanjing The First Affiliated Hospital with Nanjing Medical Universiโ€ฆ ยท Tests: anti-CD19/BCMA-UCAR-T cells Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) NCT06350110Phase 1, Phase 21 site๐Ÿ“ Beijing Essen Biotech ยท Tests: CD19- BCMA CAR-T cells CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases NCT06941129Phase 11 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: UCAR T-cell NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis NCT06676631Phase 11 site๐Ÿ“ Guangzhou Guangdong Provincial People's Hospital ยท Tests: NK 010 or NK042, Rituximab Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases NCT06685042Phase 1, Phase 21 site๐Ÿ“ Rome Fondazione Policlinico Universitario Agostino Gemelli IRCCS ยท Tests: CAR T cell CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases NCT07315087Phase 11 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: QT-019C An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases NCT07174843EARLY Phase 11 site๐Ÿ“ Shanghai Shanghai Cell Therapy Group Co.,Ltd ยท Tests: CD19/CD22/BCMA CAR-T cells(BZE2204) BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases NCT06794008Phase 21 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: BCMA-CD19 CAR-T therapy Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia NCT06826430Phase 11 site๐Ÿ“ Beijing Juventas Cell Therapy Ltd. ยท Tests: Inaticabtagene autoleucel Injection A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis NCT07570862Phase 212 sites๐Ÿ“ Beverly Hills๐Ÿ“ Fontana๐Ÿ“ Fullerton Fate Therapeutics ยท Tests: FT819 Blinatumomab in Refractory Active Childhood Systemic Lupus Erythematosus NCT06789107Phase 12 sites๐Ÿ“ Hangzhou๐Ÿ“ Hangzhou Mao Jianhua ยท Tests: Blinatumomab 9ug A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases NCT06978647Phase 11 site๐Ÿ“ Beijing China Immunotech (Beijing) Biotechnology Co., Ltd. ยท Tests: YTS109 cell Alnuctamab for Refractory SLE (LATTE Study) NCT07219563Phase 11 site๐Ÿ“ New York Icahn School of Medicine at Mount Sinai ยท Tests: Alnuctamab Study of CD19 CAR-T Therapy for Refractory SLE NCT07403097Phase 11 site๐Ÿ“ Chongqing Chongqing Precision Biotech Co., Ltd ยท Tests: PTOC1 Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric Lupus NCT07425730n/a1 site๐Ÿ“ Shanghai Shanghai Jiao Tong University School of Medicine CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis NCT06785519EARLY Phase 11 site๐Ÿ“ Hangzhou He Huang ยท Tests: CD19/BCMA Lupus Nephritis Targeted CAR T-cells injection Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease NCT06497361EARLY Phase 11 site๐Ÿ“ Wuhan Tongji Hospital ยท Tests: PRG-2311 Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus NCT06400537Phase 12 sites๐Ÿ“ Wuhan๐Ÿ“ Taiyuan Union Hospital, Tongji Medical College, Huazhong Universityโ€ฆ ยท Tests: A-319 Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE NCT07318259Phase 11 site๐Ÿ“ Nanjing Chongqing Precision Biotech Co., Ltd ยท Tests: BCMA/CD70 CAR-T cells CD19/BCMA CAR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus NCT06349343Phase 11 site๐Ÿ“ Wuhan Union Hospital, Tongji Medical College, Huazhong Universityโ€ฆ ยท Tests: CD19/BCMA CAR-T cell therapy Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases NCT07085676Phase 11 site๐Ÿ“ Jerusalem Polina Stepensky ยท Tests: HBI0101 CART IASO207 Injection for Active Refractory Systemic Lupus Erythematosus (SLE) NCT07617740EARLY Phase 11 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: IASO207 Injection Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases NCT07121777NA1 site๐Ÿ“ Hefei Anhui Provincial Hospital ยท Tests: Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus NCT06691152Phase 11 site๐Ÿ“ Hangzhou The Children's Hospital of Zhejiang University School of Meโ€ฆ ยท Tests: CD19 Universal CAR-T cells A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases NCT07115745Phase 128 sites๐Ÿ“ Boston๐Ÿ“ Durham๐Ÿ“ Camperdown Juno Therapeutics, Inc., a Bristol-Myers Squibb Company ยท Tests: BMS-986515, Fludarabine, Cyclophosphamide, Tocilizumab
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy